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Abstract 
Background: Gemcitabine and docetaxel have been shown to be active in pre‑treated relapsed leiomyosarcoma. 
This study investigated the combination as first line treatment in patients with unresectable locally advanced/meta‑
static leiomyosarcoma.
Methods: Patients received gemcitabine 900 mg/m2 days 1 and 8, and docetaxel 100 mg/m2 day 8, administered 
3‑weekly for up to 8 cycles, with GCSF support on days 9–15. Patients who had received previous radiotherapy were 
treated at 75% dose. Patients were evaluated for response by RECIST 1.0 after cycles 2, 4, 6 and 8, and 3‑monthly after 
completing treatment.
Results: Forty‑four patients were evaluable for response. Eligible patients had histologically proven leiomyosarcoma 
of the uterus (54.5%) or other sites (45.5%). Thirty‑nine patients (84.4%) had metastatic disease, and 5 (15.6%) had 
locally advanced disease. Six patients (13.6%) had grade 1 disease, and 23 (75%) had grade 2/3 disease. All patients 
had demonstrated disease progression prior to trial entry. Responses were as follows: partial response 11 (25.0%), sta‑
ble disease (confirmed) 16 (36.6%), stable disease (unconfirmed) 7 (15.9%), progressive disease 10 (22.7%). Median 
progression‑free survival and overall survival were 7.1 months (95% CI 5.7–8.3) and 17.9 months (95% CI 10.6–25.2), 
respectively. Progression free rates at 3 and 6 months were 70.5% (95% CI 56.7–84.2%) and 59.1% (95% CI 44.3–73.9%).
Conclusions: This study demonstrates gemcitabine and docetaxel to be active in locally advanced/metastatic leio‑
myosarcoma in the first line setting. Further investigation comparing with current standard therapies for leiomyosar‑
coma is warranted.
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Background
Leiomyosarcoma represents one of the commonest sub-
types of soft tissue sarcoma (STS). It can arise at any ana-
tomical location, but the commonest sites are the female 
gynaecological organs (26%), limbs (16%), gastrointestinal 
tract (14%), trunk (13%), and retroperitoneum (6%) [1]. The 
age-standardised incidence of leiomyosarcoma in England 
for 2007–2009 was 9/million, with 470 cases in 2009 [1].
Outcomes for locally advanced unresectable or meta-
static STS are poor, with a median OS of 12 months [2]. 
Chemotherapy is usually the initial treatment, and for 
many years the first line treatment has been single agent 
doxorubicin or combination doxorubicin and ifosfamide 
[3]. Most recently a prospective randomised phase III 
study has shown that while combination doxorubicin 
chemotherapy is associated with a longer PFS com-
pared with doxorubicin alone, there was no difference 
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in median OS between the two groups, at 14.3 and 
12.8  months, respectively [4]. As yet, no other chemo-
therapy regimen has proved to be superior to doxoru-
bicin-based regimens. However, for more than a decade 
there has been increasing use of the combination of fixed 
dose rate gemcitabine with docetaxel, which has shown 
encouraging activity in leiomyosarcoma, both uterine 
[5–7] and non-uterine [7, 8], and in STS more gener-
ally [8–10]. Fixed-dose rate gemcitabine refers to infus-
ing the gemcitabine at a rate that maintains the plasma 
concentration of gemcitabine at levels that optimise its 
conversion into gemcitabine diphosphate (dFdCDP) and 
triphosphate (dFdCTP). The conversion process is satu-
rable, hence the benefit of prolonged infusion. dFdCDP is 
an inhibitor of ribonucleotide reductase, and dFdCTP is 
incorporated into deoxyribonucleic acid (DNA) causing 
strand termination during DNA replication. Preclinical 
data indicate that maintaining the dFdCTP concentra-
tion at ≥20 μmol/l optimises tumour cell killing in vivo 
[11, 12]. Pharmacokinetic studies from a phase II study 
in leiomyosarcoma have shown that using fixed dose 
rate gemcitabine (10 mg/m2/min) increased the duration 
of time that dFdCTP remained above the threshold for 
incorporation into DNA, as compared with bolus gemcit-
abine [8].
The purpose of this study was to confirm the response 
rates observed in the previous studies of gemcitabine and 
docetaxel in STS, and to limit the cohort to leiomyosar-
coma in the first line setting.
Methods
Patient eligibility
Patients with advanced unresectable leiomyosarcoma, 
of uterine origin or other sites of origin were eligible for 
this phase II study. All patients were recruited at either 
of two specialist sarcoma units. Other eligibility criteria 
were as follows: one or more sites of measurable disease 
according to RECIST 1.0 (which should not be within a 
previously irradiated field); no previous chemotherapy, 
but prior radiation allowed if completed >6 weeks prior 
to trial entry; adequate organ function (absolute neutro-
phil count ≥1 × 109/l, platelet count ≥100 × 109/l, total 
bilirubin ≤21  μmol/l, serum creatinine ≤130  μmol/l); 
performance status 0–2; no previous history of malig-
nancy other than non-melanoma skin cancer or cervical 
carcinoma in situ; patients not pregnant or lactating; no 
active uncontrolled infection; no evidence of grade 3 or 
4 peripheral neuropathy. All external histopathology was 
reviewed centrally by expert sarcoma pathologists at the 
two sarcoma centres.
All patients provided written informed consent form 
prior to study entry. Ethical permissions were given by 
both institutions’ Institutional Review Boards, and by the 
UK NHS Research Ethics Committee.
Treatment
At study entry patients were evaluated with baseline his-
tory and clinical examination, blood tests and imaging 
[computerised tomography (CT)] scan of chest, abdomen 
and pelvis. During treatment, prior to each cycle patients 
were assessed for treatment-related toxicities, and under-
went clinical examination, and blood tests (including 
weekly full blood counts, and urea, electrolytes and liver 
function) prior to each cycle. Disease response was eval-
uated by CT scans which were repeated prior to cycles 3, 
5 and 7, and at the end of treatment, and then 3-monthly 
thereafter until disease progression.
Patients without a previous history of pelvic radiother-
apy received fixed dose rate (10 mg/m2/min) gemcitabine 
900  mg/m2 on days 1 and 8 given intravenously over 
90 min, followed by docetaxel 100 mg/m2 on day 8 given 
intravenously over 60  min, for up to 8 cycles. Patients 
who had received previous pelvic radiotherapy were 
treated at 25% lower doses (gemcitabine 675 mg/m2 and 
docetaxel 75  mg/m2). Premedication used for docetaxel 
was dexamethasone 8 mg twice daily for 3 days starting 
the on day 7. Human recombinant granulocyte colony-
simulating factor support was used with lenograstim 
(Granocyte™, Chugai Pharma UK Ltd) 263 μg daily sub-
cutaneously on days 9–15.
Treatment toxicities were assessed according to 
the National Cancer Institute Common Toxicity Cri-
teria version 2.0. If during a cycle platelets fell to 
<25  ×  109/l for >5  days and/or there was an episode 
of febrile neutropenia then doses of gemcitabine and 
docetaxel were reduced by 25% for all subsequent 
cycles. If on day 1 platelets were <100 × 109/l or abso-
lute neutrophil count (ANC) was <1.0  ×  109/l, then 
treatment was delayed for a week. If platelets or ANC 
had not recovered after a 2-week delay, then patients 
were removed from the study. If on day 8 ANC was 
0.5–0.99 × 109/l and/or platelets were 50–99 × 109/l, 
then gemcitabine and docetaxel doses were reduced by 
25%. If on day 8 ANC was <0.5 ×  109/l and/or plate-
lets were <50 × 109/l then gemcitabine and docetaxel 
were omitted for that cycle. If grade 3 or 4 neurotox-
icity occurred, treatment was delayed by 1  week; if 
toxicity had resolved to ≤grade 2, then treatment was 
continued with a 25% dose reduction of docetaxel for 
all subsequent cycles. If bilirubin was >21  μmol/l, 
docetaxel was withheld for that cycle, and reinstated 
if bilirubin fell to ≤21  μmol/l. For any other grade 3 
or 4 non-haematological toxicities, treatment should 
be delayed until resolution to ≤grade 2; if toxicity had 
Page 3 of 7Seddon et al. Clin Sarcoma Res  (2015) 5:13 
not recovered after a 2-week delay, then patients were 
removed from the study.
All serious adverse events occurring during the treat-
ment period and within 30 days after the end of the last 
protocol treatment were reported to the Research Ethics 
Committee.
Disease response evaluation
All patients who received at least 2 cycles of study treat-
ment were considered assessable for response. Response 
was assessed by tumour measurements made accord-
ing to RECIST 1.0 [13]. The best overall response was the 
best response recorded from the start of treatment until 
disease progression/recurrence (taking as reference for 
progressive disease the smallest measurements recorded 
since the treatment started). To be assigned a status of par-
tial response (PR) or complete response (CR), changes in 
tumour measurements were confirmed by repeat assess-
ments performed no less than 4 weeks after the criteria for 
response were first met. In the case of stable disease (SD), 
follow-up measurements must have met the SD criteria at 
least once after study entry at a minimal interval defined in 
the protocol (in this case after 2 cycles of treatment).
Statistical design
This was a phase II trial designed to have a 90% chance of 
concluding that the study treatment was effective if its true 
response rate was ≥35%, but with only a 5% chance of con-
cluding it was effective if the response rate was ≤15%.
The trial had a Simon two-stage accrual design with an 
early stopping rule in the event that the study treatment 
demonstrated insufficient activity. Nineteen patients were 
to be recruited in the first stage, and 25 patients in the 
second stage, giving a possible total of 44 patients. If there 
were fewer than four responses in the first stage, the trial 
would be stopped early. If the study was completed, but 
there were fewer than 11 responses overall, then the study 
treatment would be considered inactive. If there were 
≥4 responses in the first 19 patients and a total of ≥11 
responses overall (≥25% response rate) then it would be 
concluded that the study treatment has sufficient activity 
to warrant further investigation in clinical trials.
The primary endpoint of the study was the objective 
response rate (ORR). Secondary end points were PFS, 
OS, and toxicity. The proportions of patients surviving 
and progression free during follow-up were calculated 
using the Kaplan–Meier method, and median follow-up 
was calculated using the reverse Kaplan–Meier method.
Results
Patient characteristics
Between August 2004 and December 2007, 45 patients 
were enrolled from two sarcoma units in London, UK. 
One patient was excluded from the analysis as she only 
received one cycle of chemotherapy and so was consid-
ered non-evaluable for response (this patient deteriorated 
rapidly after cycle 1 and died). No patients had received 
prior adjuvant chemotherapy. Patient and disease charac-
teristics are summarised in Table 1.






 Male 5 11.4
 Female 39 88.6
Primary site of disease
 Uterus 24 54.5
 Retroperitoneum 7 15.9
 Other 7 15.9
 Extremity 2 4.5
 Vascular 2 4.5
 Thoracic 1 2.3
 Not known 1 2.3
Disease type
 Locally advanced 5 11.4
 Metastatic 39 88.6
Tumour grade
 Grade 1 6 13.6
 Grade 2 10 22.7
 Grade 3 23 52.3
 Not known 5 11.4
Site of metastases
 Lung 31 70.4
 Liver 17 38.6
 Soft tissue 17 38.6
 Viscera 6 13.6
 Bone 4 9.1
 None 5 11.3
Number of metastatic sites
 0 5 11.3
 1 16 26.4
 2 13 29.5
 3 8 18.2
 4 2 4.5
Previous radiotherapy
 None 30 68.2
 Pelvic 9 20.5
 Other site 5 11.4
Previous surgery
 Yes 36 81.8
 No 8 18.2
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Treatment and toxicity
The median number of cycles of study treatment per 
patient was 6 (range 2–8 cycles). Eleven patients (25.0%) 
received 2 cycles, 4 (9.1%) received 3 cycles, 4 (9.1%) 
received 4 cycles, 2 (4.5%) received 5 cycles, 13 (29.5%) 
received 6 cycles, 1 (2.3%) received 7 cycles, and 9 
(20.5%) received 8 cycles. Nine patients required a dose 
reduction (25% in 8 patients, 50% in 1 patient). Of these, 
8 patients started at 100% dose, and 1 patient at 75% dose 
due to previous pelvic radiotherapy.
Toxicities observed with the study treatment are sum-
marised in Table 2. The commonest toxicities (any grade) 
were anaemia (95%), fatigue (93%), alopecia (88%), and 
thrombocytopenia (71%). The commonest grade 3 or 4 
toxicities were fatigue (30%), anaemia (24%), dyspnoea 
(16%), neutropenia (12%), and infection (any, 12%). Eight 
patients (18%) stopped study treatment early specifically 
due to toxicity.
Treatment response and survival
RECIST-measured objective PR were observed in 11 
patients (25%), and 16 patients (36.4%) achieved con-
firmed SD. A further 7 patients (15.9%) had SD that was 
unconfirmed by RECIST, and 10 patients (22.7%) had 
disease progression. Comparing uterine versus non-
uterine primary site, PR were seen in 8 (33%) and 3 (15%) 
patients, respectively, and confirmed SD in 7 patients 
(29.3%) and 8 (40%) patients, respectively.
At a median follow-up of 41  months, the median 
PFS was 7.1  months (95% confidence interval, CI, 5.7–
8.3  months) (Figure  1), with progression-free rates at 3 
and 6  months of 70.5% (95% CI 56.7–84.2%) and 59.1% 
(95% CI 44.3–73.9%), respectively. The median OS was 
17.9  months (95% CI 10.6–25.2  months), with OS rates 
at 12 and 24 months of 65.5% (95% CI 51.1–79.9%) and 
33.6% (95% CI 18.8–48.4%), respectively.
Post‑progression treatment
After treatment within the study, further treatment was 
as follows: 31 patients received second line systemic 
therapy (doxorubicin n = 31, ifosfamide n = 1, letrozole 
n = 1, pazopanib n = 1), 12 patients received third line 
systemic therapy (clinical trial n = 3, trabectedin n = 5, 
megesterol acetate n = 1, ifosfamide n = 2, gemcitabine 
and docetaxel n = 1), and 1 patient received fourth line 
systemic therapy (ifosfamide). Two patients underwent 
surgery (1 patient underwent palliative resection of resid-
ual pelvic disease, 1 patient underwent resection of a 
Table 2 Adverse events related to the study treatment
Adverse event NCI common toxicity criteria grade
1 2 3 4 Any (%) Total
Neutropenia 5 4 1 4 14 (30) 42
Thrombocytopenia 19 8 1 2 30 (71) 42
Anaemia 13 17 8 2 40 (95) 42
Infection 16 8 5 0 29 (67) 43
Vomiting 11 4 3 0 18 (43) 42
Diarrhoea 14 7 4 0 25 (58) 43
Dyspnoea 3 11 5 2 21 (49) 43
Fatigue 13 14 12 1 40 (93) 43
Neuropathy 19 2 0 0 21 (49) 43
Allergy 5 0 0 1 6 (14) 43
Alopecia 11 26 0 0 37 (88) 42
Joint pain 15 9 0 0 24 (56) 43
Figure 1 Kaplan–Meier curve of progression‑free survival (days) for 
patients with advanced leiomyosarcoma (n = 44). Median progres‑
sion free survival 7.1 months (95% CI 5.7–8.3 months).
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uterine mass that was deemed inoperable prior to chem-
otherapy), 2 patients received palliative radiotherapy 
alone, 6 patients had no further treatment, and informa-
tion was missing for 2 patients.
Discussion
Doxorubicin-based chemotherapy has remained the first 
line treatment for locally advanced/metastatic STS since 
its introduction nearly 40 years ago [3]. In that time no 
alternative regimen has been shown to be superior. How-
ever, there has been increasing recognition in recent 
years that it is no longer appropriate to consider all STSs 
as one homogeneous group, and that individual STS sub-
types may respond differentially to different treatment 
regimens [14–16]. One of the earliest indications of using 
a specific treatment regimen in a STS subtype was the 
use of gemcitabine and docetaxel in  leiomyosarcoma 
(Table 3). An initial study, predominantly in patients with 
uterine primary tumours, reported an ORR of 53% and 
median time to progression of 5.6 months [8]. The sug-
gestion that there might be increased benefit for uterine 
leiomyosarcoma led to the investigation of the regimen in 
this patient group with phase II studies in the first [6] and 
second [5] line setting for advanced metastatic disease, 
with median PFS of 4.4 and 6.7  months, respectively. It 
has also been used in this patient cohort in the adjuvant 
setting in two phase II studies [17, 18], and has shown 
sufficient promise for it to now be studied in an interna-
tional prospective randomised phase III study of adjuvant 
gemcitabine and docetaxel for 4 cycles followed by doxo-
rubicin for 4 cycles, compared with observation for early 
stage resected uterine leiomyosarcoma (NCT01979393).
Gemcitabine and docetaxel have been investigated in 
leiomyosarcoma as a specific group with the randomised 
phase II TAXOGEM study, which comparing with single 
agent gemcitabine for metastatic/relapsed disease in the 
second line setting [7]. It was stratified for uterine and 
non-uterine leiomyosarcoma, but was not able to dem-
onstrate any difference between the two groups. Gem-
citabine alone appeared to yield similar results to the 
combination but with less toxicity.
Our study was conceived following the publication 
of the first phase II study [8], with the aim of trying to 
replicate the early promising results, but in a cohort of 
leiomyosarcoma patients with locally advanced/meta-
static disease in the first line setting. We have shown an 
ORR of 25%, with a 36.4% of patients achieving SD (with 
RECIST confirmation), giving a crude clinical benefit rate 
of 61.4%. A further 15.9% of patients had SD but without 
RECIST confirmation. The median PFS was 7.1 months, 
with a progression-free rate at 3 and 6  months of 70.5 
and 59.1%, respectively. These results are consistent with 
the other studies summarised in Table  3. Patients went 
on to receive a range of treatments subsequent to trial 
participation, predominantly with further chemotherapy 
as would be expected in the context of metastatic disease.
Our patients received a median of 6 cycles of chemo-
therapy, and indeed only 20% completed the full 8 cycles. 
The commonest toxicities were fatigue and anaemia, 
experienced by >90% of patients. Dose reductions were 
required in 20% of patients, and treatment was stopped 
early in 18% specifically due to toxicity. Hence, the regi-
men as given in this study was relatively toxic, which 
needs to be borne in mind for chemotherapy being given 
in a non-curative, palliative setting.
The use of gemcitabine and docetaxel has been 
extended beyond leiomyosarcoma to STSs in general, 
and a randomised phase II study of 122 patients has 
compared the combination with gemcitabine alone [19], 
showing both regimens to be active, but with supe-
rior PFS for the combination (6.2  months) compared 
with gemcitabine alone (3.0  months). However, patients 
receiving the combination had a higher probability of 
stopping treatment early due to toxicity.
Table 3 Phase II studies of gemcitabine and docetaxel in locally advanced/metastatic leiomyosarcoma





f Results reported for uLMS and LMS separately.
Study Na uLMSb LMSc Line of treatment Median PFSd (months) 3 month PFRe (%) 6 month PFR (%)
Hensley et al. [8] 34 ✓ ✓ 1st and 2nd 5.6 – 47
Hensley et al. [6] 42 ✓ – 1st 4.4 59.5 40.5
Hensley et al. [5] 48 ✓ – 2nd 6.7+ 73 52
Pautier et al. [7] 46 ✓ ✓ 2nd 3.4–4.7f 53–71f 47–48f
This study 44 ✓ ✓ 1st 7.1 70.5 59.1
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Despite the increasing evidence in the phase II setting 
to support the use of gemcitabine and docetaxel in STS, 
there has as yet been no phase III comparison with the 
current standard of care. We therefore decided to con-
duct a prospective randomised phase III study (GeDDiS) 
of gemcitabine and docetaxel compared with doxoru-
bicin, in locally advanced/metastatic STS in the first line 
setting (CRUK/10/004). This study has been designed to 
compare efficacy and toxicity, and also includes health 
economic and quality of life data collection, in order to 
fully compare the two regimens. In view of the toxicity 
findings of our phase II study, we decided to use lower 
chemotherapy doses (75% of those used in the phase II 
study), and to limit treatment to 6 cycles. Recruitment 
has been conducted across the United Kingdom and 
Switzerland, and was completed with the accrual of 254 
patients in January 2014. Initial results are anticipated in 
2015.
Conclusions
In conclusion, we have confirmed previous findings of 
the activity of gemcitabine and docetaxel in the first line 
setting in locally advanced/metastatic leiomyosarcoma, 
showing it to be a regimen worthy of further investiga-
tion. Our study has led to an international UK-based 
phase III study of gemcitabine and docetaxel com-
pared with doxorubicin in locally advanced/metastatic 
STS, which has just completed recruitment. Results are 
awaited with interest to understand how this schedule 
fits into the current treatment algorithm for systemic 
treatment of STS.
Authors’ contributions
BMS participated in trial coordination and data collection; data analysis; 
drafted the manuscript. MS participated in trial coordination and data collec‑
tion. ZW participated in trial coordination and data collection. CP‑L partici‑
pated in trial coordination and data collection. CF carried out central review of 
pathology specimens. AF carried out central review of pathology specimens. 
JS participated in data collection and analysis. RAH carried out the statistical 
analysis. JW participated in trial coordination and data collection. IJ conceived 
the study and participated in study design; participated in trial coordination 
and data collection. All authors read and approved the final manuscript.
Author details
1 Sarcoma Unit, University College Hospital, 1st Floor Central, 250 Euston 
Road, London NW1 2PG, UK. 2 Sarcoma Unit, Royal Marsden Hospital, Fulham 
Road, London SW3 6JJ, UK. 3 Department of Histopathology, Royal National 
Orthopaedic Hospital, Brockley Hill, Stanmore, Middlesex HA7 4LP, UK. 4 ICR 
Clinical Trials and Statistics Unit, Institute of Cancer Research, 15 Cotswold 
Road, Sutton SM2 5NG, UK. 
Acknowledgements
This research was partly undertaken at UCLH/UCL and was supported by the 
National Institute for Health Research (NIHR) University College London Hospi‑
tals Biomedical Research Centre, and by the Royal Marsden Hospital/Institute 
of Cancer Research NIHR Biomedical Research Centre.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 6 April 2015   Accepted: 5 May 2015
References
 1. Dennis NF, Francis M, Lawrence G (2012) Soft tissue sarcoma incidence 
and survival: tumours diagnosed in England between 1985 and 2009. 
United Kingdom: National Cancer Intelligence Network, December 2012. 
Report No: R12/06
 2. Karavasilis V, Seddon BM, Ashley S, Al‑Muderis O, Fisher C, Judson I 
(2008) Significant clinical benefit of first‑line palliative chemotherapy in 
advanced soft‑tissue sarcoma: retrospective analysis and identification of 
prognostic factors in 488 patients. Cancer 112(7):1585–1591
 3. Sleijfer S, Seynaeve C, Verweij J (2005) Using single‑agent therapy in 
adult patients with advanced soft tissue sarcoma can still be considered 
standard care. Oncologist 10(10):833–841
 4. Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay J‑Y et al 
(2014) Doxorubicin alone versus intensified doxorubicin plus ifosfamide 
for first‑line treatment of advanced or metastatic soft‑tissue sarcoma: a 
randomised controlled phase 3 trial. Lancet Oncol 15(4):415–423
 5. Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG, Homesley 
HD (2008) Fixed‑dose rate gemcitabine plus docetaxel as second‑line 
therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology 
Group phase II study. Gynecol Oncol 109(3):323–328
 6. Hensley ML, Blessing JA, Mannel R, Rose PG (2008) Fixed‑dose rate 
gemcitabine plus docetaxel as first‑line therapy for metastatic uterine 
leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol 
Oncol 109(3):329–334
 7. Pautier P, Floquet A, Penel N, Piperno‑Neumann S, Isambert N, Rey A 
et al (2012) Randomized multicenter and stratified phase II study of 
gemcitabine alone versus gemcitabine and docetaxel in patients with 
metastatic or relapsed leiomyosarcomas: a Federation Nationale des Cen‑
tres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study 
(TAXOGEM study). Oncologist 17(9):1213–1220
 8. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian 
C et al (2002) Gemcitabine and docetaxel in patients with unresectable 
leiomyosarcoma: results of a phase II trial. J Clin Oncol 20(12):2824–2831
 9. Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS 
et al (2004) Laboratory and clinical evidence of synergistic cytotoxicity 
of sequential treatment with gemcitabine followed by docetaxel in the 
treatment of sarcoma. J Clin Oncol 22(9):1706–1712
 10. Bay JO, Ray‑Coquard I, Fayette J, Leyvraz S, Cherix S, Piperno‑Neumann 
S et al (2006) Docetaxel and gemcitabine combination in 133 advanced 
soft‑tissue sarcomas: a retrospective analysis. Int J Cancer J Int du Cancer 
119(3):706–711
 11. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B et al 
(1991) A phase I clinical, plasma, and cellular pharmacology study of 
gemcitabine. J Clin Oncol 9(3):491–498
 12. Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett 
W (1990) Pharmacologically directed design of the dose rate and 
schedule of 2′,2′‑difluorodeoxycytidine (Gemcitabine) administration in 
leukemia. Cancer Res 50(21):6823–6826
 13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L 
et al (2000) New guidelines to evaluate the response to treatment in solid 
tumors. European Organization for Research and Treatment of Cancer, 
National Cancer Institute of the United States, National Cancer Institute of 
Canada. J Natl Cancer Inst 92(3):205–216
 14. Penel N, Bui BN, Bay JO, Cupissol D, Ray‑Coquard I, Piperno‑Neumann S 
et al (2008) Phase II trial of weekly paclitaxel for unresectable angiosar‑
coma: the ANGIOTAX Study. J Clin Oncol 26(32):5269–5274
Page 7 of 7Seddon et al. Clin Sarcoma Res  (2015) 5:13 
 15. Wagner AJ, Malinowska‑Kolodziej I, Morgan JA, Qin W, Fletcher CD, 
Vena N et al (2010) Clinical activity of mTOR inhibition with sirolimus in 
malignant perivascular epithelioid cell tumors: targeting the pathogenic 
activation of mTORC1 in tumors. J Clin Oncol 28(5):835–840
 16. (MetaGIST) GstM‑aG (2010) Comparison of two doses of imatinib for the 
treatment of unresectable or metastatic gastrointestinal stromal tumors: 
a meta‑analysis of 1,640 patients. J Clin Oncol 28(7):1247–1253
 17. Hensley ML, Ishill N, Soslow R, Larkin J, Abu‑Rustum N, Sabbatini P et al 
(2009) Adjuvant gemcitabine plus docetaxel for completely resected 
stages I–IV high grade uterine leiomyosarcoma: results of a prospective 
study. Gynecol Oncol 112(3):563–567
 18. Hensley ML, Wathen JK, Maki RG, Araujo DM, Sutton G, Priebat DA et al 
(2013) Adjuvant therapy for high‑grade, uterus‑limited leiomyosarcoma: 
results of a phase 2 trial (SARC 005). Cancer 119(8):1555–1561
 19. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B et al 
(2007) Randomized phase II study of gemcitabine and docetaxel 
compared with gemcitabine alone in patients with metastatic soft tissue 
sarcomas: results of sarcoma alliance for research through collaboration 
study 002 [corrected]. J Clin Oncol 25(19):2755–2763
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
